first-line nivolumab ipilimumab in metastatic uveal melanoma
Published 3 years ago • 84 plays • Length 3:16Download video MP4
Download video MP3
Similar videos
-
4:31
metastatic uveal melanoma show durable response to ipilimumab and nivolumab combination after pd-1
-
2:44
cancer immunotherapy with nivolumab plus ipilimumab vs. chemotherapy: insights from checkmate 227
-
0:49
scandium 2: ihp with ipilimumab and nivolumab in uveal melanoma metastases
-
6:19
should you treat melanoma with nivolumab and relatlimab (opdualag)?
-
4:50
ipilimumab/nivolumab in first-line mrcc
-
1:06
current and future treatment options for uveal melanoma
-
6:01
metastatic rcc: using frontline ipilimumab/nivolumab
-
1:28
treating uveal melanoma liver metastases with isolated hepatic perfusion
-
3:16
optimizing the use of ipilimumab/nivolumab in mrcc
-
7:36
mrcc patient selection for ipilimumab/nivolumab
-
5:31
checkmate-227: nivolumab ipilimumab in mnsclc
-
1:55
dr. jeffrey weber on ipilimumab for melanoma
-
1:34
dr. sharpless on managing toxicities with nivolumab/ipilimumab in melanoma
-
1:54
dr. lenz on updated data from checkmate 142 with nivolumab ipilimumab in mcrc
-
1:00
prime-hcc: ipilimumab and nivolumab in liver cancer
-
2:35
dr. atkins on long-term survival benefit of nivolumab/ipilimumab in advanced melanoma
-
8:01
fda activity for nivolumab, t-vec in melanoma, new lung cancer findings, mds findings, and more
-
1:01
rana mckay, md, discusses checkmate214 investigating nivolumab ipilimumab in 1st line rcc patients